RxDoctor Payments Data

Lawrence Chang, MD

Internal Medicine · San Clemente, CANPI 1528046430

Payments from drug & device makers

$3,923in general payments, 2019–2025

Across 97 payments — averaging $40.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Globus Medical$1K
  • Johnson & Johnson$587
  • Abbott$526
  • Novartis$425
  • Pfizer$311
  • Inari Medical, Inc.$177
  • plus $852 from 14 others

What the payments were for

  • Travel & lodging$1,00126%
  • Food & beverage$2,92174%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,923 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$124,339
Medicare patients
273
Services billed
1,186

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban107$107,254
XareltoRivaroxaban87$81,537
OzempicSemaglutide40$37,001
RybelsusSemaglutide32$30,157
JanuviaSitagliptin Phosphate14$23,625
MyrbetriqMirabegron15$11,578
Breo ElliptaFluticasone/Vilanterol25$9,842
SynthroidLevothyroxine Sodium67$4,753
Levothyroxine Sodium364$4,046
Atorvastatin Calcium368$3,412
Acyclovir41$2,995
PaxlovidNirmatrelvir/Ritonavir44$2,797
Colchicine14$2,284
Memantine Hcl59$2,066
Valsartan66$2,008

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$311$110,051151 claims
Johnson & JohnsonXarelto$587$81,53787 claims
Novo NordiskOzempic, Rybelsus$43$67,15872 claims
MerckJanuvia$25$23,62514 claims
GSKBreo Ellipta$165$9,84225 claims
AbbVieSynthroid$59$4,75367 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Clemente

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →